The JAG2 Knockout PaTu 8988t Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population that stably disrupts the human JAG2 gene in the PaTu 8988t background. This product provides a heterogeneous pool of cells carrying targeted gene disruptions, enabling functional studies of JAG2 without clonal isolation. The polyclonal format preserves biological variability while reliably reducing JAG2 expression, making it suitable for loss-of-function experiments in pancreatic cancer models. As a mixed population, it offers a robust system to assess the collective impact of JAG2 ablation on cellular phenotypes, avoiding potential biases from single-cell clones.
The host cell line, PaTu 8988t, is an epithelial cell line established from a liver metastasis of a human pancreatic ductal adenocarcinoma (PDAC). It carries two critical oncogenic mutations: KRAS G12V and TP53 mutations, mirroring the genetic landscape of aggressive PDAC. This metastatic origin and driver mutation profile render PaTu 8988t highly relevant for studying advanced pancreatic cancer biology, including metastasis, therapy resistance, and epithelial-mesenchymal transition (EMT). The cells are widely used as a model system for investigating PDAC pathogenesis and for preclinical drug testing.
JAG2 encodes Jagged-2, a canonical ligand of the Notch signaling pathway, which governs cell fate determination, proliferation, and differentiation. Upon binding to NOTCH1 or NOTCH3 receptors, Jagged-2 triggers proteolytic cleavage by ADAM17, releasing the Notch intracellular domain (NICD) that complexes with RBPJ to transcriptionally activate downstream effectors such as HES1, HEY1, SNAI1, and TWIST1. JAG2 expression is regulated by upstream factors including MYC and HIF1A. The JAG2-NOTCH1-NICD-RBPJ-HES1 axis is a representative signaling cascade through which Jagged-2 promotes stemness and EMT. Disruption of JAG2 abrogates ligand-receptor engagement, attenuating downstream transcriptional programs.
In the context of PaTu 8988t, JAG2 knockout is predicted to compromise the malignant phenotype. Given the role of Notch signaling in PDAC progression, loss of JAG2 may reduce cell proliferation, diminish cancer stem cell properties, and reverse EMT, as suggested by the downregulation of SNAI1 and TWIST1. Moreover, Notch pathway inhibition has been associated with enhanced sensitivity to gemcitabine and other chemotherapeutics, positioning this knockout model as a valuable tool to explore synergistic treatment strategies. The KRAS/TP53-mutant background further accentuates the relevance for translational research in pancreatic adenocarcinoma.
The JAG2 Knockout PaTu 8988t Polyclonal Cells are ideally suited for a broad spectrum of investigations, including pancreatic cancer biology, Notch signaling, drug resistance, and EMT studies. Typical applications involve assessing changes in cell proliferation, migration, and invasion, as well as drug sensitivity profiling. Researchers can employ a variety of assays such as western blotting, RT-qPCR, flow cytometry, and RNA-seq to characterize the knockout phenotype and its downstream consequences. This model provides a reliable platform for dissecting JAG2-dependent mechanisms and for screening candidate therapeutics. For further information, please contact Ascent Research.
